The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp is set to present its latest research on regulatory RNAs aimed at increasing gene expression in haploinsufficiency diseases at the 2026 Cancer Epigenetics Institute Symposium, hosted by Fox Chase Cancer Center and sponsored by Biomodalhq.
Dan Tardiff, PhD, Chief Scientific Officer of Camp4 Therapeutics Corp, will highlight the company’s approach to deploying regulatory RNAs as a novel solution for conditions where gene activity is insufficient. The presentation underscores ongoing innovation in epigenetic therapies and could signal future advances for rare disease treatment.